EP
BCAX

Essential Partners’s Bicara Therapeutics BCAX Stock Holding History

Essential Partners’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267 Hold
9
– – ﹤0.01% 2590
2026
Q1 		$179 Hold
9
– – ﹤0.01% 2629
2025
Q4 		$151 Hold
9
– – ﹤0.01% 2488
2025
Q3 		$142 Buy
9
+5
+125% +$56 ﹤0.01% 2450
2025
Q2 		$37 Buy
+4
New +$48 ﹤0.01% 2180

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's BCAX Position: Q2 2026 in Review

Essential Partners held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 9 shares worth $267. The position accounts for ﹤0.01% of the portfolio, ranked #2590.

Essential Partners first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Essential Partners held 9 shares of Bicara Therapeutics worth $267 as of Q2 2026.
  • Essential Partners left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2590 holding.
  • Essential Partners first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.